Verition Fund Management LLC Has $366,000 Position in Becton Dickinson and Co (BDX)

Verition Fund Management LLC cut its holdings in Becton Dickinson and Co (NYSE:BDX) by 82.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,691 shares of the medical instruments supplier’s stock after selling 7,799 shares during the quarter. Verition Fund Management LLC’s holdings in Becton Dickinson and were worth $366,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Hilltop Holdings Inc. purchased a new stake in shares of Becton Dickinson and in the first quarter valued at approximately $575,000. Amundi Pioneer Asset Management Inc. boosted its stake in shares of Becton Dickinson and by 11.7% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 624,771 shares of the medical instruments supplier’s stock valued at $135,388,000 after buying an additional 65,220 shares in the last quarter. First Commonwealth Financial Corp PA boosted its stake in shares of Becton Dickinson and by 37.0% in the first quarter. First Commonwealth Financial Corp PA now owns 4,074 shares of the medical instruments supplier’s stock valued at $883,000 after buying an additional 1,101 shares in the last quarter. Glenview Trust Co purchased a new stake in shares of Becton Dickinson and in the first quarter valued at approximately $407,000. Finally, Mariner LLC boosted its stake in shares of Becton Dickinson and by 108.2% in the first quarter. Mariner LLC now owns 4,992 shares of the medical instruments supplier’s stock valued at $1,081,000 after buying an additional 2,594 shares in the last quarter. Hedge funds and other institutional investors own 84.08% of the company’s stock.

A number of research firms recently weighed in on BDX. ValuEngine upgraded Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. upgraded Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 target price on the stock in a research report on Thursday, June 21st. BMO Capital Markets began coverage on Becton Dickinson and in a research report on Monday, March 5th. They set a “market perform” rating and a $249.00 target price on the stock. Zacks Investment Research downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Finally, Citigroup upgraded Becton Dickinson and from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $237.00 to $251.00 in a research report on Tuesday, April 10th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and an average target price of $237.29.

In related news, insider Alexandre Conroy sold 20,128 shares of the company’s stock in a transaction on Monday, May 21st. The stock was sold at an average price of $228.74, for a total value of $4,604,078.72. Following the completion of the transaction, the insider now directly owns 35,583 shares in the company, valued at $8,139,255.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nabil Shabshab sold 10,209 shares of the company’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $226.10, for a total value of $2,308,254.90. Following the completion of the transaction, the executive vice president now owns 12,476 shares of the company’s stock, valued at $2,820,823.60. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.

NYSE BDX opened at $239.50 on Wednesday. Becton Dickinson and Co has a fifty-two week low of $191.53 and a fifty-two week high of $248.39. The firm has a market capitalization of $62.73 billion, a PE ratio of 25.26, a P/E/G ratio of 1.63 and a beta of 1.12. The company has a quick ratio of 1.12, a current ratio of 1.70 and a debt-to-equity ratio of 1.07.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.63 by $0.02. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The company had revenue of $4.22 billion during the quarter, compared to analysts’ expectations of $4.12 billion. During the same period in the previous year, the firm posted $2.30 earnings per share. The business’s revenue for the quarter was up 42.2% compared to the same quarter last year. research analysts predict that Becton Dickinson and Co will post 10.99 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 29th. Stockholders of record on Friday, June 8th will be issued a $0.75 dividend. The ex-dividend date of this dividend is Thursday, June 7th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.25%. Becton Dickinson and’s dividend payout ratio (DPR) is 31.65%.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply